Anonymous ID: 299582 Sept. 9, 2021, 7:02 a.m. No.14545837   🗄️.is 🔗kun   >>5950 >>5981 >>5987 >>6288

Constitutionally, they can’t force you to get vaccinated but they can force your employer, your church, your doctor, your local government, your DMV, your local merchant, your local restaurant, gym, car dealer, gas station, your schools etc to force you?

 

Which is still unconstitutional medical discrimination done by deputized proxy.

See: "…I was just following orders"

Anonymous ID: 299582 Sept. 9, 2021, 7:07 a.m. No.14545863   🗄️.is 🔗kun

>>14545842

>Joe Manchin needs to join the Republican Party too instead of pretending that communism isn’t knocking at America’s door.

 

Joe Manchin and those 19 other Republicans need to stop pretending that communism isn’t knocking at America’s door.

Anonymous ID: 299582 Sept. 9, 2021, 7:14 a.m. No.14545906   🗄️.is 🔗kun

>>14545897

>President Biden to announce that all federal workers must be vaccinated, with no option for testing

 

My body, my choice. Fuck off, bankrupt employer.

Anonymous ID: 299582 Sept. 9, 2021, 7:17 a.m. No.14545924   🗄️.is 🔗kun   >>5944

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH;Pfizer Inc.;Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.